403 related articles for article (PubMed ID: 28822777)
21. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
22. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
Yassin SA; Aroda VR
Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
[TBL] [Abstract][Full Text] [Related]
23. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
24. Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents.
Goldenberg RM
Can J Diabetes; 2011 Dec; 35(5):518-27. PubMed ID: 24854977
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
Sharma A; Verma S
Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
[TBL] [Abstract][Full Text] [Related]
26. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
[TBL] [Abstract][Full Text] [Related]
27. Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.
DeFilippis EM; Givertz MM
Curr Heart Fail Rep; 2016 Jun; 13(3):111-8. PubMed ID: 27188181
[TBL] [Abstract][Full Text] [Related]
28. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin JA
Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
[TBL] [Abstract][Full Text] [Related]
29. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
30. Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.
Egger A; Kraenzlin ME; Meier C
Curr Osteoporos Rep; 2016 Dec; 14(6):345-350. PubMed ID: 27709509
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease.
Makino Y; Fujita Y; Haneda M
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):67-73. PubMed ID: 25415611
[TBL] [Abstract][Full Text] [Related]
32. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
van Baar MJB; van Raalte DH
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
[TBL] [Abstract][Full Text] [Related]
33. Novel therapeutic agents for the treatment of diabetic kidney disease.
Hartman RE; Rao PSS; Churchwell MD; Lewis SJ
Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584
[TBL] [Abstract][Full Text] [Related]
34. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
35. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
36. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
Schernthaner G; Mogensen CE; Schernthaner GH
Diab Vasc Dis Res; 2014 Sep; 11(5):306-23. PubMed ID: 25116004
[TBL] [Abstract][Full Text] [Related]
37. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet MH; Smits MM; Morsink LM; Diamant M
Nat Rev Nephrol; 2014 Feb; 10(2):88-103. PubMed ID: 24375052
[TBL] [Abstract][Full Text] [Related]
38. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
Muskiet MHA; Tonneijck L; Smits MM; van Baar MJB; Kramer MHH; Hoorn EJ; Joles JA; van Raalte DH
Nat Rev Nephrol; 2017 Oct; 13(10):605-628. PubMed ID: 28869249
[TBL] [Abstract][Full Text] [Related]
39. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
Dejager S; Schweizer A
Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
[TBL] [Abstract][Full Text] [Related]
40. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
